Chiltern acquires Drug Development Solutions business
Global contract research organisation Chiltern has acquired the business of Drug Development Solutions (DDS), a leading Phase 1 unit located at Ninewells Hospital and Medical School, one of the UK's major teaching hospitals located in Dundee, Scotland. The purchase supplements Chiltern's Clinical Research Unit in Slough near London.
Global contract research organisation Chiltern has acquired the business of Drug Development Solutions (DDS), a leading Phase 1 unit located at Ninewells Hospital and Medical School, one of the UK's major teaching hospitals located in Dundee, Scotland. The purchase supplements Chiltern's Clinical Research Unit in Slough near London.
Founded in 1982, DDS has completed more than 700 Phase I trials. The unit offers 42 high intensity care beds with the ability to expand these to 60. The unit is located within a major hospital that can provide emergency medical services if required, allowing it to attain the higher level of voluntary accreditation available for Phase 1 units from the UK regulator, the MHRA. The unit has special expertise in first-in-man studies and is a world leader in systemic drug phototoxicity studies in humans.
Dr Brian Sanderson, ceo and medical director of DDS, will continue to lead the Dundee unit and will work closely with Chiltern's existing Clinical Research Unit to build its early phase service offering. DDS will trade as Chiltern with immediate effect.
"This move allows us to offer leading edge Phase I services to our global client base and supplements our existing early phase capability and strong Phase II - IV capacities," said Glenn Kerkhof, Chiltern's ceo. "The UK has long been a centre of excellence for early phase clinical pharmacology and once again offers a stable regulatory environment and internationally competitive approval timelines."